-
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to regular approval for Elahere (mirvetuximab soravtansine) has been accepted by the National Medical Products Administration (NMPA). This antibody drug conjugate (ADC) targets folate receptor α (FRα) and represents a significant step forward in the treatment…
-
Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for Elahere (mirvetuximab soravtansine), an antibody drug conjugate (ADC) targeting folate receptor α (FRα), for the treatment of FRα positive platinum-resistant ovarian cancer (PROC) in patients who have…
-
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
•
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug conjugate (ADC) Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval marks Elahere as the first and…
-
AbbVie to Acquire ImmunoGen for USD 10.1 Billion, Expanding Oncology Portfolio
•
AbbVie (NYSE: ABBV) has reached an agreement to acquire fellow U.S. biotech ImmunoGen (NASDAQ: IMGN) for an equity value of approximately USD 10.1 billion. The transaction is anticipated to close in mid-2025, pending the fulfillment of customary regulatory conditions. This acquisition will enhance AbbVie’s portfolio with Elahere (mirvetuximab soravtansine), an…
-
Huadong Medicine’s Elahere Accepted for NMPA Review in China for Ovarian Cancer Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted the market filing for its antibody drug conjugate (ADC) Elahere (mirvetuximab soravtansine), targeting folate receptor α (FRα). This marks a significant step towards making the treatment available for patients in China. Acquisition…
-
Takeda Secures Exclusive Rights to ImmunoGen’s Elahere in Japan Through New Agreement
•
Japanese pharmaceutical company Takeda (TYO: 4502) has entered into an exclusive collaboration and license agreement with ImmunoGen (NASDAQ: IMGN) to develop and commercialize ImmunoGen’s antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine) in Japan. Elahere has received accelerated approval in the United States for the treatment of FRα-positive platinum-resistant epithelial ovarian, fallopian…
-
Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab soravtansine), an antibody drug conjugate (ADC) targeting folate receptor α (FRα), at Ruijin Hospital’s Hainan branch. The treatment is indicated for FRα positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in…
-
Biosion and ImmunoGen Collaborate on Cancer ADCs
•
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with US firm ImmunoGen, Inc. (Nasdaq: IMGN). Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company, and ImmunoGen will provide…
